Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

So in the upcoming large scale P2b/3 study,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Doc328 Member Profile
 
Followed By 34
Posts 1,260
Boards Moderated 0
Alias Born 03/04/18
160x600 placeholder
Nightfood, Inc. (OTCQB: NGTF) Significant Retail Expansion InvestorsHub NewsWire - 7/21/2021 6:47:54 AM
CEO Presenting on the Emerging Growth / Investors Hub Joint Conference on July 21 InvestorsHub NewsWire - 7/20/2021 7:00:00 AM
Alzheimer's drug players shake off concerns from Biogen aducanunab probe Seeking Alpha - 7/12/2021 10:20:38 AM
CEO Presenting on the Second Emerging Growth / Investors Hub Joint Conference on July 7. InvestorsHub NewsWire - 7/5/2021 7:00:00 AM
WNRS Upgraded To BUY InvestorsHub NewsWire - 7/1/2021 9:36:27 AM
Sino United (OTC Pink: SUIC) $200 Million Commitment, Signs with Suntech, the Largest Taiwan O2O Company. InvestorsHub NewsWire - 6/30/2021 7:30:00 AM
Anavex posts the sharpest one-day loss in over seven months Seeking Alpha - 6/29/2021 4:49:18 PM
Anavex posts the sharpest one-day loss in over seven months Seeking Alpha - 6/29/2021 4:47:49 PM
Anavex Life stock soars 16% after ANAVEX2-73 improved endpoints in Phase 2 Parkinson’s disease study Seeking Alpha - 6/28/2021 7:29:25 AM
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy E... GlobeNewswire Inc. - 6/28/2021 7:00:00 AM
Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering GlobeNewswire Inc. - 6/24/2021 4:15:00 PM
CLNV Signals VERY BULLISH After News On Deal Developing To Target $55 Billion Plastic Waste-To-Energy Sector InvestorsHub NewsWire - 6/24/2021 11:02:01 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/24/2021 8:47:25 AM
CLNV Targets $300 Billion Food Packaging Industry With Environmentally Sustainable Biodegradable Alternative InvestorsHub NewsWire - 6/22/2021 9:55:37 AM
Anavex Life under pressure on launch of $50M direct offering Seeking Alpha - 6/22/2021 7:40:05 AM
Anavex Life Sciences Announces $50 Million Registered Direct Offering GlobeNewswire Inc. - 6/22/2021 7:00:00 AM
Anavex Life shares gain 8% as ANAVEX2-73 shows correlation with efficacy endpoints in mid-stage rett syndrome study Seeking Alpha - 6/21/2021 8:15:46 AM
CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference on June 23. Register Now InvestorsHub NewsWire - 6/21/2021 7:00:00 AM
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled... GlobeNewswire Inc. - 6/21/2021 7:00:00 AM
Clearside Biomedical, Eloxx Pharmaceuticals leads healthcare gainers; PDS Biotechnology, Sage Therapeutics among major losers Seeking Alpha - 6/15/2021 11:02:54 AM
Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease Seeking Alpha - 6/14/2021 8:41:57 AM
Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ... GlobeNewswire Inc. - 6/14/2021 7:00:00 AM
CEO's Presenting at Emerging Growth Conference Virtually Tomorrow InvestorsHub NewsWire - 6/8/2021 7:00:00 AM
Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b... GlobeNewswire Inc. - 6/8/2021 7:00:00 AM
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment ... GlobeNewswire Inc. - 6/3/2021 7:00:00 AM
Doc328   Saturday, 08/04/18 10:44:10 AM
Re: tradeherpete post# 161445
Post # of 322574 
Quote:
So in the upcoming large scale P2b/3 study, in 450 patients with early AD, we are planning to look at 2 aspects again, stratification regarding the genomics of the patients. We look at Wild types of the S1R gene carriers vs variant receptor carriers. And we expect a differential response depending on the genetic background.




So, it looks like they will be enrolling all genetic types. Thus, about 360 patients will be S1R-WT and about 90 patients will be S1R-var. Then at study end they will analyze the data stratified by the gene.

The proposed P2/3 looks well designed (placebo controlled, randomized, standard outcomes such as ADAS-cog and CDR-SB, etc)and should be large enough to get real data. I look forward to those results. The only thing I don't like about the study is that they have MMSE 20-28 as inclusion criteria (based on HH's slide at AAIC) and many MMSE 27 and 28 (MCI not mild AD) patients would not be expected to decline over 48 weeks. This potentially weakens a treatment effect if the numbers of these patients are too high.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences